Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

Abstract

The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.